logo
logo
AI + EXCLUSIVE DATA

AI tracks executive moves from sources others don't have

Our proprietary AI analyzes exclusive hiring data to find decision-makers actively evaluating solutions like yours.

10-25 executive leads daily • Direct contact info • First 90 days targeting
Start with:
✓Flexible Plans • $39/mo or $29/mo annual
✓AI + proprietary hiring database
✓Executive contact details included
INDUSTRY FIRST

Adma Biologics Announces Executive Leadership Changes

Feb 28, 2024•over 1 year ago

Position

Chief Financial Officer

Company

ADMA Biologics

Adam Grossman
RamseyBiopharmaBiotechnologyManufacturing

Description

ADMA Biologics announces the transition of Brian Lenz from Executive Vice President, Chief Financial Officer & General Manager, ADMA BioCenters to a consulting role, effective April 1, 2024. Adam Grossman is appointed as Interim Chief Financial Officer and the company has initiated an executive search for a full-time replacement Chief Financial Officer.

Company Information

Company

ADMA Biologics

Location

Ramsey, New Jersey, United States

About

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases.

Company News

(4 articles)
Wed, 30 Jul 2025 07:00:00 GMT

ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025 - The Globe and Mail

Fri, 28 Feb 2025 08:00:00 GMT

ADMA Biologics to Participate in the Raymond James Institutional Investor Conference - GlobeNewswire

Wed, 30 Jul 2025 07:00:00 GMT

ADMA Biologics Earnings: Biopharma Leader Sets Q2 2025 Financial Results Release for August 6 - Stock Titan

Wed, 30 Apr 2025 07:00:00 GMT

ADMA Biologics Q1 2025 Earnings: Key Financial Updates Coming May 7 for Growing Biopharmaceutical Leader - Stock Titan

FundzWatch™ Score

73
Medium Activity

Related People

Sign in to view contact details

Sign in to view contact details

Executive Insights

Based on hiring data
New executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months